71825-51-9

Usage

Uses

Used in Pharmaceutical Industry:
2-methyl-2-(4-nitrophenyl)propanenitrile is used as a synthetic intermediate for the production of various pharmaceuticals. Its functional groups facilitate the creation of new compounds with potential medicinal properties, contributing to the development of novel drugs and therapeutic agents.
Used in Dye and Pigment Production:
In the dye and pigment industry, 2-methyl-2-(4-nitrophenyl)propanenitrile is utilized as a key component in the synthesis of dyes and pigments. Its chemical structure allows for the development of colorants with specific properties, such as color intensity and stability, which are essential for various applications, including textiles, plastics, and printing inks.
Used in Organic Chemical Synthesis:
2-methyl-2-(4-nitrophenyl)propanenitrile is employed as a versatile building block in the synthesis of a wide range of organic chemicals. Its nitrile and nitro groups enable it to participate in various chemical reactions, leading to the formation of new compounds with diverse applications in the chemical, material, and pharmaceutical industries.
It is important to handle 2-methyl-2-(4-nitrophenyl)propanenitrile with care due to its potential toxicity and environmental impact. Proper safety measures and disposal methods should be followed to minimize any adverse effects on human health and the environment.

InChI:InChI=1/C10H10N2O2/c1-10(2,7-11)8-3-5-9(6-4-8)12(13)14/h3-6H,1-2H3

Upstream product

• 74-88-4 methyl iodide 
• 851233-80-2 potassium 2-cyano-2-methyl-propanoate 
• 100-00-5 4-chlorobenzonitrile 
• 1195-98-8 2-methyl-2-phenylpropionitrile 
• 71-91-0 tetraethylammonium bromide 
• 555-21-5 4-Nitrophenylacetonitrile 
• 14500-58-4 4-nitrocumyl chloride 
• 143-33-9 sodium cyanide 

Downstream Products

• 145208-37-3 N-<4-(1-Cyano-1-methylethyl)phenyl>-5-methylisoxazole-4-carboxamide 
• 1416000-70-8 ethyl 6-chloro-4-((4-(2-cyanopropan-2-yl)phenyl)amino)-1,5-naphthyridine-3-carboxylate 
• 1610680-66-4 2-(4-(8-amino-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1610680-65-3 2-methyl-2-(4-(3-methyl-8-morpholino-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1201646-92-5 2-(4-((3'-amino[3,6'-biquinolin]-4'-yl)amino)phenyl)-2-methyl propanenitrile 
• 1610680-64-2 2-methyl-2-(4-(3-methyl-8-(4-methylpiperazin-1-yl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1610680-72-2 2-(4-(8-(benzo[b]thiophen-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1370615-16-9 2-methyl-2-(4-(3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1610680-71-1 2-methyl-2-(4-(3-methyl-2-oxo-8-(6-(trifluoromethyl)pyridin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1628077-34-8 2-(4-(8-iodo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1610680-70-0 2-methyl-2-(4-(3-methyl-2-oxo-8-phenyl-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1628077-36-0 2-(4-((3-amino-6-iodoquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile 

Relevant academic research and scientific papers

Cobalt-catalyzed C[sbnd]H activation/C[sbnd]O formation: Synthesis of benzofuranones

Herein, C[sbnd]H activation/C[sbnd]O formation reaction using novel cobalt catalytic system is reported. This reaction was given benzofuranones in moderate to excellent yields at room-temperature under air reaction conditions. The introduced strategy is efficient and low-cost method to synthesized benzofuranones from α,α-disubstitution acetic acid.

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Imidazole derivatives, its pharmaceutical composition and use thereof

Imidazolone compounds, pharmaceutically acceptable salts, solvates, polymorphs or prodrugs thereof are disclosed. Pharmaceutical compositions comprising above substances and uses for preventing and treating protein kinases related diseases, such as cancers, metabolic diseases, cardiovascular diseases and the like, are also disclosed.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

JAK PI3K/mTOR combination therapy

Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.

Five-membered urea link and coumarin derivative or its pharmaceutically acceptable salts and use

The invention relates to a small molecule medicament based on PI3K (Phosphatidyl Inositol 3-kinase)/mTOR (Mammalian Target of Rapamycin) double targets, belongs to the technical field of chemical medicines, and in particular relates to a five-membered urea ring-coumarin derivative or a pharmaceutical salt and an application thereof. A compound claimed by the invention has a structure shown as formula I described in the specification, and pharmacological experiments show that the compound has excellent inhibitory activity in a plurality of tumor cell strains.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation

A series of quinoline derivatives featuring the novelty of introducing intra-molecular hydrogen bonding scaffold (iMHBS) were designed, synthesized and biologically evaluated for their mTOR inhibitory activity, as well as anti-proliferative efficacies aga

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.